行情

CTMX

CTMX

CytomX医疗
NASDAQ

实时行情|Nasdaq Last Sale

7.76
-0.23
-2.88%
盘后: 7.76 0 0.00% 16:00 04/07 EDT
开盘
8.12
昨收
7.99
最高
8.27
最低
7.60
成交量
43.72万
成交额
--
52周最高
12.63
52周最低
3.595
市值
3.54亿
市盈率(TTM)
-3.4435
分时
5日
1月
3月
1年
5年

分析师评级

12位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测CTMX价格均价为13.82,最高价位19.00,最低价为7.00。

EPS

CTMX 新闻

更多
  • 沪指跌幅收窄跌0.32% 隔夜美股高台跳水、油价尾盘杀跌
  • 新浪财经 · 10分钟前
  • 高盛:在紧急状态之下日本经济本季将萎缩25%
  • 新浪财经 · 23分钟前
  • 特朗普:已就石油问题与俄罗斯和沙特通话 事情会解决的
  • 新浪财经 · 27分钟前
  • 龚宇回应爱奇艺被做空:老老实实做人,踏踏实实做事
  • 新浪科技 · 29分钟前

所属板块

生物技术和医学研究
-2.20%
制药与医学研究
-1.62%

热门股票

代码
价格
涨跌幅

CTMX 简况

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies. Its product candidates include CX-072, CX-2009, CX-2029, Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and CX-188. Its Probody platform utilizes active proteases in tumor tissue to allow monoclonal antibody-based therapies. Its investigational Probody therapeutics address clinically validated cancer targets in immuno-oncology, such as programmed death-ligand 1, against which CX-072 is directed, as well as targets, such as cluster of differentiation 166, against, which CX-2009 is directed.
展开

微牛提供CytomX Therapeutics Inc(NASDAQ-CTMX)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的CTMX股票新闻,以帮助您做出投资决策。